Ubs Group Ag Immix Biopharma, Inc. Transaction History

Ubs Group Ag

$611 Billion
Q3 2025

A detailed history of Ubs Group Ag transactions in Immix Biopharma, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 1,940 shares of IMMX stock, worth $8,167. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,940

Previous 13,972 86.12%

Holding current value

$8,167

Previous $28,000 85.71%

% of portfolio

0.0%

Previous 0.0%

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 13, 2025	SELL	$1.96 - $2.99 $23,582 - $35,975	-12,032 Reduced 86.12%	1,940 $4,000
Q2 2025 Aug 14, 2025	BUY	$1.36 - $2.6 $5,237 - $10,012	3,851 Added 38.05%	13,972 $28,000
Q1 2025 May 13, 2025	SELL	$1.52 - $2.35 $6,212 - $9,604	-4,087 Reduced 28.77%	10,121 $17,000
Q4 2024 Feb 14, 2025	BUY	$1.38 - $2.54 $11,125 - $20,477	8,062 Added 131.17%	14,208 $32,000
Q3 2024 Nov 14, 2024	BUY	$1.49 - $2.45 $4,458 - $7,330	2,992 Added 94.86%	6,146 $9,000

Q2 2024 Aug 13, 2024	SELL	$1.81 - $3.06 $3,808 - $6,438	-2,104 Reduced 40.02%	3,154 $6,000
Q1 2024 May 13, 2024	BUY	$2.64 - $6.68 $6,943 - $17,568	2,630 Added 100.08%	5,258 $16,000
Q4 2023 Feb 09, 2024	BUY	$2.82 - $7.27 $7,410 - $19,105	2,628 New	2,628 $18,000
Q1 2023 May 12, 2023	SELL	$1.72 - $3.14 $4,103 - $7,492	-2,386 Reduced 50.91%	2,301 $4,000
Q4 2022 Feb 08, 2023	SELL	$0.75 - $2.43 $5,487 - $17,780	-7,317 Reduced 60.95%	4,687 $10,000
Q3 2022 Nov 10, 2022	BUY	$1.36 - $3.05 $10,427 - $23,384	7,667 Added 176.78%	12,004 $16,000
Q2 2022 Aug 10, 2022	BUY	$1.3 - $2.97 $5,638 - $12,880	4,337 New	4,337 $11,000
Q1 2022 May 16, 2022	SELL	$1.86 - $6.75 $60,727 - $220,380	-32,649 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$2.95 - $4.0 $96,314 - $130,596	32,649 New	32,649 $116,000

Others Institutions Holding IMMX

# of Institutions

Shares Held

3.15M

Call Options Held

Put Options Held

View Full List

About Immix Biopharma, Inc.

Ticker IMMX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 13,910,100
Market Cap $58.6M
Description
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing various tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specif...

More about IMMX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account